The North American Neuroendocrine Tumor Society Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors

Lenders, 2005, Phaeochromocytoma., Lancet, 366, 665, 10.1016/S0140-6736(05)67139-5

Manger, 2002, Pheochromocytoma., J Clin Hypertens, 4, 62, 10.1111/j.1524-6175.2002.01452.x

Van Duinen, 2010, Increased urinary excretion of 3-methoxytyramine in patients with head and neck paragangliomas., J Clin Endocrinol Metab, 95, 209, 10.1210/jc.2009-1632

Elder, 2005, Pheochromocytoma and functional paraganglioma syndrome: no longer the 10% tumor., J Surg Oncol, 89, 193, 10.1002/jso.20177

Neumann, 2002, Germ-line mutations in nonsyndromic pheochromocytoma., N Engl J Med, 346, 1459, 10.1056/NEJMoa020152

Barontini, 2006, Characteristics of pheochromocytoma in a 4- to 20-year-old population., Ann N Y Acad Sci, 1073, 30, 10.1196/annals.1353.003

De Krijger, 2006, Frequent genetic changes in childhood pheochromocytomas., Ann N Y Acad Sci, 1073, 166, 10.1196/annals.1353.017

Benn, 2006, Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes., J Clin Endocrinol Metab, 91, 827, 10.1210/jc.2005-1862

Gimenez-Roqueplo, 2003, Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas., Cancer Res, 63, 5615

Bryant, 2003, Pheochromocytoma: the expanding genetic differential diagnosis., J Natl Cancer Inst, 95, 1196, 10.1093/jnci/djg024

Brouwers, 2006, High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing., J Clin Endocrinol Metab, 91, 4505, 10.1210/jc.2006-0423

Timmers, 2007, Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas., J Clin Endocrinol Metab, 92, 779, 10.1210/jc.2006-2315

Amar, 2005, Genetic testing in pheochromocytoma or functional paraganglioma., J Clin Oncol, 23, 8812, 10.1200/JCO.2005.03.1484

Lenders, 2002, Biochemical diagnosis of pheochromocytoma: which test is best?, JAMA, 287, 1427, 10.1001/jama.287.11.1427

Eisenhofer, 1999, Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2., N Engl J Med, 340, 1872, 10.1056/NEJM199906173402404

Sawka, 2003, A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines., J Clin Endocrinol Metab, 88, 553, 10.1210/jc.2002-021251

Lenders, 2007, Is supine rest necessary before blood sampling for plasma metanephrines?, Clin Chem, 53, 352, 10.1373/clinchem.2006.076489

Grossman, 2006, Biochemical diagnosis and localization of pheochromocytoma: can we reach a consensus?, Ann N Y Acad Sci, 1073, 332, 10.1196/annals.1353.038

Eisenhofer, 2003, Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results., J Clin Endocrinol Metab, 88, 2656, 10.1210/jc.2002-030005

Baid, 2009, Contrast enhanced computed tomography does not induce catecholamine release in patients with pheochromocytoma., Ann Intern Med, 150, 27, 10.7326/0003-4819-150-1-200901060-00006

Pacak, 2004, Functional imaging of endocrine tumors: role of positron emission tomography., Endocr Rev, 25, 568, 10.1210/er.2003-0032

Lumachi, 2006, Sensitivity and positive predictive value of CT, MRI and 123I-MIBG scintigraphy in localizing pheochromocytomas: a prospective study., Nucl Med Commun, 27, 583, 10.1097/00006231-200607000-00006

van der Harst, 2001, (123)Imetaiodobenzylguanidine and (111)Inoctreotide uptake in benign and malignant pheochromocytomas., J Clin Endocrinol Metab, 86, 685

Van Der Horst-Schrivers AN, Jager, 2006, Iodine-123 metaiodobenzylguanidine scintigraphy in localising phaeochromocytomas-experience and meta-analysis., Anticancer Res, 26, 1599

Bhatia, 2008, 123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation., Clin Endocrinol (Oxf), 69, 181, 10.1111/j.1365-2265.2008.03256.x

Mackenzie, 2007, The use of 18-fluoro-dihydroxyphenylalanine and 18-fluorodeoxyglucose positron emission tomography scanning in the assessment of metaiodobenzylguanidine-negative phaeochromocytoma., Eur J Endocrinol, 157, 533, 10.1530/EJE-07-0369

Ilias, 2003, Superiority of 6-18F-fluorodopamine positron emission tomography versus 131I-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma., J Clin Endocrinol Metab, 88, 4083, 10.1210/jc.2003-030235

Hoegerle, 2002, Pheochromocytomas: detection with 18F DOPA whole body PET-initial results., Radiology, 222, 507, 10.1148/radiol.2222010622

Timmers, 2007, The effects of carbidopa on uptake of 6-18F-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma., J Nucl Med, 48, 1599, 10.2967/jnumed.107.042721

Shulkin, 1993, Pheochromocytomas that do not accumulate metaiodobenzylguanidine: localization with PET and administration of FDG., Radiology, 186, 711, 10.1148/radiology.186.3.8430179

Shulkin, 1999, Pheochromocytomas: imaging with 2-fluorine-18fluoro-2-deoxy-D-glucose PET., Nucl Med, 212, 35

Timmers, 2007, Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma., J Clin Oncol, 25, 2262, 10.1200/JCO.2006.09.6297

Pacak, 2007, Pheochromocytoma: recommendations for clinical practice from the first international symposium., Nat Clin Pract Endocrinol Metab, 3, 92, 10.1038/ncpendmet0396

Pacak, 2007, Preoperative management of the pheochromocytoma patient., J Clin Endocrinol Metab, 92, 4069, 10.1210/jc.2007-1720

Goldstein, 1999, 3rd, et al. Clinical experience over 48 years with pheochromocytoma., Ann Surg, 229, 755, 10.1097/00000658-199906000-00001

Hack, 2000, The perioperative management of children with phaeochromocytoma., Paediatr Anaesth, 10, 463, 10.1046/j.1460-9592.2000.00504.x

Gedik, 2008, 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma., Eur J Nucl Med Mol Imaging, 35, 725, 10.1007/s00259-007-0652-6

Averbuch, 1988, Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine., Ann Intern Med, 109, 267, 10.7326/0003-4819-109-4-267

van Essen, 2006, Effects of therapy with 177Lu-DOTA0, Tyr3octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma., J Nucl Med, 47, 1599

Pelizzo, 2007, Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients., Eur J Surg Oncol, 33, 493, 10.1016/j.ejso.2006.10.021

Moley, 1999, Hereditary endocrinopathies., Curr Probl Surg, 36, 653, 10.1016/S0011-3840(99)80001-X

Ball, 2007, Medullary thyroid cancer: therapeutic targets and molecular markers., Curr Opin Oncol, 19, 18, 10.1097/CCO.0b013e32801173ea

Roman, 2006, Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases., Cancer, 107, 2134, 10.1002/cncr.22244

Lal, 2007, Radioguided parathyroidectomy in patients with familial hyperparathyroidism., Ann Surg Oncol, 14, 739, 10.1245/s10434-006-9254-y

Sippel, 2008, Current management of medullary thyroid cancer., Oncologist, 13, 539, 10.1634/theoncologist.2007-0239

Hansford, 2000, Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis review., J Med Genet, 37, 817, 10.1136/jmg.37.11.817

Kouvaraki, 2005, RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors., Thyroid, 15, 531, 10.1089/thy.2005.15.531

Brandi, 2001, Guidelines for diagnosis and therapy of MEN type 1 and type 2., J Clin Endocrinol Metab, 86, 5658, 10.1210/jcem.86.12.8070

Cohen, 2000, Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d'Etudes des Tumeurs a Calcitonine (GETC)., J Clin Endocrinol Metab, 85, 919, 10.1210/jcem.85.2.6556

Barbet, 2005, Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma., J Clin Endocrinol Metab, 90, 6077, 10.1210/jc.2005-0044

Quayle, 2004, Hereditary medullary thyroid carcinoma in patients greater than 50 years old., Surgery, 136, 1116, 10.1016/j.surg.2004.05.057

Tung, 1995, Laparoscopic detection of hepatic metastases in patients with residual or recurrent medullary thyroid cancer., Surgery, 118, 1024, 10.1016/S0039-6060(05)80109-6

Skinner, 2005, Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A., N Engl J Med, 353, 1105, 10.1056/NEJMoa043999

Moley, 1999, Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection., Ann Surg, 229, 880, 10.1097/00000658-199906000-00016

Greenblatt, 2007, Initial lymph node dissection increases cure rates in patients with medullary thyroid cancer., Asian J Surg, 30, 108, 10.1016/S1015-9584(09)60141-X

Machens, 2007, Increased risk of lymph node metastasis in multifocal hereditary and sporadic medullary thyroid cancer., World J Surg, 31, 1960, 10.1007/s00268-007-9185-1

Scollo, 2003, Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer., J Clin Endocrinol Metab, 88, 2070, 10.1210/jc.2002-021713

Kebebew, 2005, Extent of disease and practice patterns for medullary thyroid cancer., J Am Coll Surg, 200, 890, 10.1016/j.jamcollsurg.2004.12.011

Chen, 1998, Effective long-term palliation of symptomatic, incurable metastatic medullary thyroid cancer by operative resection., Ann Surg, 227, 887, 10.1097/00000658-199806000-00012

de Groot, 2007, A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma., J Clin Endocrinol Metab, 92, 3466, 10.1210/jc.2007-0649

Wells, 2010, Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer., J Clin Oncol, 28, 767, 10.1200/JCO.2009.23.6604

Schlumberger, 2009, Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer., J Clin Oncol, 27, 3794, 10.1200/JCO.2008.18.7815

Sherman, 2008, Motesanib diphosphate in progressive differentiated thyroid cancer., N Engl J Med, 359, 31, 10.1056/NEJMoa075853

Moley, 1998, Surgical management of patients with persistent or recurrent medullary thyroid cancer., J Intern Med, 243, 521, 10.1046/j.1365-2796.1998.00333.x

Moley, 1993, Reoperation for recurrent or persistent medullary thyroid cancer., Surgery, 114, 1090

Van Gompel, 2005, ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells., Mol Cancer Ther, 4, 910, 10.1158/1535-7163.MCT-04-0334

Ning, 2008, Suberoyl bishydroxamic acid activates notch1 signaling and suppresses tumor progression in an animal model of medullary thyroid carcinoma., Ann Surg Oncol, 15, 2600, 10.1245/s10434-008-0006-z

Kunnimalaiyaan, 2007, Inactivation of glycogen synthase kinase-3 beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells., Mol Cancer Ther, 6, 1151, 10.1158/1535-7163.MCT-06-0665

Kunnimalaiyaan, 2006, Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002., Surgery, 140, 1009, 10.1016/j.surg.2006.06.040

Kunnimalaiyaan, 2006, Overexpression of the NOTCH1 intracellular domain inhibits cell proliferation and alters the neuroendocrine phenotype of medullary thyroid cancer cells., J Biol Chem, 281, 39819, 10.1074/jbc.M603578200

Sippel, 2003, The role of human achaete-scute homolog-1 in medullary thyroid cancer cells., Surgery, 134, 866, 10.1016/S0039-6060(03)00418-5

Greenblatt, 2008, Valproic acid activates Notch1 signaling and induces apoptosis in medullary thyroid cancer cells., Ann Surg, 247, 1036, 10.1097/SLA.0b013e3181758d0e

Weise, 2002, Utility of plasma free metanephrines for detecting childhood pheochromocytoma., J Clin Endocrinol Metab, 87, 1955, 10.1210/jcem.87.5.8446

Zelinka, 2007, Pheochromocytoma as a catecholamine producing tumor: implications for clinical practice., Stress, 10, 195, 10.1080/10253890701395896